Cargando…
Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an appro...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404220/ https://www.ncbi.nlm.nih.gov/pubmed/32698349 http://dx.doi.org/10.3390/ijms21145114 |
_version_ | 1783567104848429056 |
---|---|
author | Miyamoto, Kenichi Minami, Yosuke |
author_facet | Miyamoto, Kenichi Minami, Yosuke |
author_sort | Miyamoto, Kenichi |
collection | PubMed |
description | Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML. |
format | Online Article Text |
id | pubmed-7404220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74042202020-08-11 Cutting Edge Molecular Therapy for Acute Myeloid Leukemia Miyamoto, Kenichi Minami, Yosuke Int J Mol Sci Review Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML. MDPI 2020-07-20 /pmc/articles/PMC7404220/ /pubmed/32698349 http://dx.doi.org/10.3390/ijms21145114 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Miyamoto, Kenichi Minami, Yosuke Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title | Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title_full | Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title_fullStr | Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title_full_unstemmed | Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title_short | Cutting Edge Molecular Therapy for Acute Myeloid Leukemia |
title_sort | cutting edge molecular therapy for acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404220/ https://www.ncbi.nlm.nih.gov/pubmed/32698349 http://dx.doi.org/10.3390/ijms21145114 |
work_keys_str_mv | AT miyamotokenichi cuttingedgemoleculartherapyforacutemyeloidleukemia AT minamiyosuke cuttingedgemoleculartherapyforacutemyeloidleukemia |